Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.36 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (papillary tip epithelial cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: vandetanib | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 222 | 0.79 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 0851
Sealed predictions
- EPHA1 in dopamine neurons, braak-0.13 (p 0.732) → -0.44 (p 0.234)receipt 0858
Swarm cases
receipt 0858: EPHA1 in dopamine neurons, braak
- power
- full sample -0.18 (p 0.465, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.20 (p 0.429, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.164, n 18). could be the mix.
- skeptic
- leave-one-out range -0.33 to -0.09, sign flips 0; without severely affected donors -0.18 (p 0.465, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EPHA1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts